Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.
2.

The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer.

Sewell R, Bäckström M, Dalziel M, Gschmeissner S, Karlsson H, Noll T, Gätgens J, Clausen H, Hansson GC, Burchell J, Taylor-Papadimitriou J.

J Biol Chem. 2006 Feb 10;281(6):3586-94. Epub 2005 Nov 30.

3.
4.

[Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].

Wang XD, Qiu L, Lu RZ, Chen LJ, Zhan ZM, Han BH, Zhang BL, Ma J.

Zhonghua Yi Xue Za Zhi. 2007 Dec 25;87(48):3399-405. Chinese.

PMID:
18476538
5.

Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.

Xu XH, Gan YC, Xu GB, Chen T, Zhou H, Tang JF, Gu Y, Xu F, Xie YY, Zhao XY, Xu RZ.

J Zhejiang Univ Sci B. 2012 Nov;13(11):867-74. doi: 10.1631/jzus.B1200021.

6.

Glycomic alterations are associated with multidrug resistance in human leukemia.

Zhang Z, Zhao Y, Jiang L, Miao X, Zhou H, Jia L.

Int J Biochem Cell Biol. 2012 Aug;44(8):1244-53. doi: 10.1016/j.biocel.2012.04.026. Epub 2012 May 11.

PMID:
22579717
7.

Effects of imatinib and 5-bromotetrandrine on the reversal of multidrug resistance of the K562/A02 cell line.

Chen BA, Shan XY, Chen J, Xia GH, Xu WL, Schmit M.

Chin J Cancer. 2010 Jun;29(6):591-5.

8.

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

Dai Y, Rahmani M, Corey SJ, Dent P, Grant S.

J Biol Chem. 2004 Aug 13;279(33):34227-39. Epub 2004 Jun 2.

9.

Alterations of O-glycan biosynthesis in human colon cancer tissues.

Yang JM, Byrd JC, Siddiki BB, Chung YS, Okuno M, Sowa M, Kim YS, Matta KL, Brockhausen I.

Glycobiology. 1994 Dec;4(6):873-84.

PMID:
7734850
10.

Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K+ channels in chronic myelogenous leukemia.

Zheng F, Li H, Liang K, Du Y, Guo D, Huang S.

Med Oncol. 2012 Sep;29(3):2127-35. doi: 10.1007/s12032-011-0102-y. Epub 2011 Dec 10.

PMID:
22161019
11.

Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness.

Gill DJ, Tham KM, Chia J, Wang SC, Steentoft C, Clausen H, Bard-Chapeau EA, Bard FA.

Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):E3152-61. doi: 10.1073/pnas.1305269110. Epub 2013 Aug 2.

12.

Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA.

Julien S, Krzewinski-Recchi MA, Harduin-Lepers A, Gouyer V, Huet G, Le Bourhis X, Delannoy P.

Glycoconj J. 2001 Nov-Dec;18(11-12):883-93.

PMID:
12820722
13.

Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.

Oh B, Kim TY, Min HJ, Kim M, Kang MS, Huh JY, Kim Y, Lee DS.

Anticancer Drugs. 2013 Jan;24(1):20-31. doi: 10.1097/CAD.0b013e32835a0fbd.

PMID:
23075630
14.

MUC1 in human and murine mammary carcinoma cells decreases the expression of core 2 β1,6-N-acetylglucosaminyltransferase and β-galactoside α2,3-sialyltransferase.

Solatycka A, Owczarek T, Piller F, Piller V, Pula B, Wojciech L, Podhorska-Okolow M, Dziegiel P, Ugorski M.

Glycobiology. 2012 Aug;22(8):1042-54. doi: 10.1093/glycob/cws075. Epub 2012 Apr 25.

15.

Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker.

Reimer TA, Anagnostopoulos I, Erdmann B, Lehmann I, Stein H, Daniel P, Dörken B, Rehm A.

BMC Cancer. 2005 May 17;5:47.

16.

Polypeptide GalNAc-transferases, ST6GalNAc-transferase I, and ST3Gal-transferase I expression in gastric carcinoma cell lines.

Marcos NT, Cruz A, Silva F, Almeida R, David L, Mandel U, Clausen H, Von Mensdorff-Pouilly S, Reis CA.

J Histochem Cytochem. 2003 Jun;51(6):761-71.

PMID:
12754287
17.

Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.

Arunasree KM, Roy KR, Anilkumar K, Aparna A, Reddy GV, Reddanna P.

Leuk Res. 2008 Jun;32(6):855-64. Epub 2008 Feb 20.

PMID:
18083230
18.

Changes in the profile of simple mucin-type O-glycans and polypeptide GalNAc-transferases in human testis and testicular neoplasms are associated with germ cell maturation and tumour differentiation.

Rajpert-De Meyts E, Poll SN, Goukasian I, Jeanneau C, Herlihy AS, Bennett EP, Skakkebaek NE, Clausen H, Giwercman A, Mandel U.

Virchows Arch. 2007 Oct;451(4):805-14. Epub 2007 Aug 11.

PMID:
17694322
19.

Molecular basis of incomplete O-glycan synthesis in MCF-7 breast cancer cells: putative role of MUC6 in Tn antigen expression.

Freire T, Bay S, von Mensdorff-Pouilly S, Osinaga E.

Cancer Res. 2005 Sep 1;65(17):7880-7.

20.

Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.

Baran Y, Bielawski J, Gunduz U, Ogretmen B.

J Cancer Res Clin Oncol. 2011 Oct;137(10):1535-44. doi: 10.1007/s00432-011-1016-y. Epub 2011 Aug 11.

PMID:
21833718
Items per page

Supplemental Content

Write to the Help Desk